Premium
Evidence vs. Access: Can Twenty‐First‐Century Drug Regulation Refine the Tradeoffs?
Author(s) -
Woodcock J
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.337
Subject(s) - clinical pharmacology , drug , productivity , pharmaceutical industry , business , pharmacology , drug development , drug pricing , medicine , economics , actuarial science , economic growth
As the pharmaceutical industry productivity crisis worsens, there are calls for regulatory changes to support innovation. At the same time, prescribers and payers desire more information about drugs at the time they are released to the market. Will new regulatory schemes be able to accommodate these disparate needs? Clinical Pharmacology & Therapeutics (2012); 91 3, 378–380. doi: 10.1038/clpt.2011.337